Day One Biopharmaceuticals reports Q3 EPS 38c, consensus (41c)

Reports Q3 revenue $93.8M, consensus $23.54M. The Company’s cash, cash equivalents and short-term investments totaled $558.4M as of September 30.”Our third quarter results demonstrate continued patient demand for OJEMDA, driven by the need for new therapies for children living with pediatric low-grade glioma,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “Looking ahead to 2025, we plan to continue to drive growth by advancing our programs and pipeline, including DAY301, a potential first-in-class ADC targeting PTK7 that we expect to be in the clinic in the coming months.”